Baricitinib + Baricitinib
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Idiopathic Inflammatory Myopathies
Conditions
Idiopathic Inflammatory Myopathies
Trial Timeline
Oct 7, 2021 → Sep 25, 2023
NCT ID
NCT04208464About Baricitinib + Baricitinib
Baricitinib + Baricitinib is a phase 2 stage product being developed by Eli Lilly for Idiopathic Inflammatory Myopathies. The current trial status is completed. This product is registered under clinical trial identifier NCT04208464. Target conditions include Idiopathic Inflammatory Myopathies.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04208464 | Phase 2 | Completed |
Competing Products
20 competing products in Idiopathic Inflammatory Myopathies